FYB Formycon AG

XETRA · DE · Healthcare · Biotechnology · formycon.com

19.10EUR+4.37%Mkt Cap: 366.91M $P/E: —Today

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular …

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap366.91M USD

Enterprise Value304.51M USD

Revenue (TTM)66.57M USD

Gross Profit3.89M USD

Net Income (TTM)-70.32M USD

Revenue/Share3.47 EUR

Last Price19.10 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees196

CountryDE

SectorHealthcare

IndustryBiotechnology

ISINDE000A1EWVY8

Valuation

P/E (Trailing)—

P/E (Forward)16.38

PEG—

EV/EBITDA29.78

EV/Revenue4.57

P/S5.28

P/B0.84

EPS (TTM)-1.42

EPS (Forward)1.12

52W Range

15.8030% of range26.95

52W High26.95 EUR

52W Low15.80 EUR

Profitability

Gross Margin8.04%

Oper. Margin-65.87%

EBITDA Margin15.36%

Profit Margin-145.46%

ROE-16.21%

ROA-8.75%

Growth

Revenue Growth242.50%

Earnings Growth—

Cash Flow & Leverage

Operating CF11.72M USD

CapEx (TTM)59.66M USD

FCF Margin-49.34%

FCF Yield-8.95%

Net Debt-47.03M USD

Net Debt/EBITDA-4.60

Balance Sheet

Debt/Equity0.02

Current Ratio2.04

Quick Ratio1.42

Book Value/Sh21.82 EUR

Cash/Share2.93 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)39.67 EUR

Upside (mean)+107.7%

Target Range30.00 EUR – 51.00 EUR

30.00+107.7% to mean51.00

# Analysts6

Ownership

Shares Out.17.67M

Float—

Insiders30.00%

Institutions31.26%

Technical

SMA 5019.36 (-1.3%)

SMA 20020.26 (-5.7%)

Beta0.72

S&P 52W Chg14.58%

Avg Vol (30d)4.73K

Avg Vol (10d)2.71K

Technical Indicators

RSI (14)39.2

MACD-0.1536

MACD Signal-0.0193

MACD Hist.-0.1343

BB Upper21.00 EUR

BB Middle19.73 EUR

BB Lower18.46 EUR

BB Width12.89%

ATR (14)0.6826 EUR

Vol Ratio (20d)2.26x